# Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

> **NCT01868451** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 118 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin (SGN-35)
- **DRUG:** Doxorubicin HCL
- **DRUG:** Vinblastine Sulfate
- **DRUG:** Dacarbazine
- **RADIATION:** Involved-Site Radiation Therapy (ISRT)
- **PROCEDURE:** Interim PET
- **RADIATION:** consolidation volume RT (CVRT)

## Key facts

- **NCT ID:** NCT01868451
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-05
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868451, "Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01868451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*